Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

48.19 -0.68 (-1.39%)
Streaming Delayed Price Updated: 11:19 AM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock. 
Via Benzinga
News headline image
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. 
Via Stocktwits
News headline image
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why ↗
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile. 
Via Benzinga
News headline image
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗
The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow. 
Via Investor's Business Daily
Topics Government
News headline image
2 No-Brainer Healthcare Stocks to Buy Now ↗
These two healthcare stocks scan as bargains right now. 
Via The Motley Fool
News headline image
Magnificent Seven Will Become Low-Profit Tech Utilities, Analyst Warns ↗
Magnificent Seven, beware. Kai Wu says Wall Street's AI darlings are shifting toward a riskier, capital-heavy model. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗
Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug. 
Via Investor's Business Daily
News headline image
Why Roche Holding Stock Popped Today ↗
Roche is great at developing drugs -- but is its stock a great buy? 
Via The Motley Fool
News headline image
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics. 
Via Investor's Business Daily
News headline image
Multimodal AI Unleashes New Era in Cancer Research: A Revolution in Diagnosis and Treatment
Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗
The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%. 
Via Investor's Business Daily
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients. 
Via Benzinga
News headline image
S&P 500's Resurgence: A Deep Dive into Market Dynamics and Future Trajectories
The S&P 500 has staged a remarkable rebound, soaring to unprecedented highs in late 2025 following a period of significant sell-off earlier in the year. This resurgence, driven by a powerful confluence... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results ↗
The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients. 
Via Investor's Business Daily
Topics Government
News headline image
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche ↗
The company took on Roche's Xolair in a 16-week study of patients with a chronic hives disorder. 
Via Investor's Business Daily
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients ↗
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile. 
Via Benzinga
News headline image
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly ↗
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older. 
Via Stocktwits
News headline image
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout ↗
The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company. 
Via Investor's Business Daily
News headline image
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market ↗
Roche has a promising GLP-1 drug that is entering phase 3 trials. 
Via The Motley Fool
News headline image
FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape
In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca... 
Via MarketMinute
News headline image
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗
Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern. 
Via Investor's Business Daily
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗
BigBear.ai is bigger than both of these AI-focused companies now. That could change. 
Via The Motley Fool
Topics Artificial Intelligence
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗
Via Stocktwits
Topics Government
News headline image
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.